Heron Therapeutics (HRTX) Receivables - Net (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Receivables - Net came in at $83.7 million in Q1 2026, up 6.3% YoY from $78.7 million in Q1 2025, and down 6.58% on a QoQ basis from $89.6 million in Q4 2025.
Heron Therapeutics (HRTX) Receivables - Net (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 12 years of Receivables - Net data on file, last reported at $83.7 million in Q1 2026.
- Quarterly Receivables - Net rose 6.3% year-over-year to $83.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.7 million (up 6.3% YoY) and the FY2025 annual result came in at $89.6 million, up 13.57% from the prior year.
- Receivables - Net fell to $83.7 million in Q1 2026, from $89.6 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $89.6 million in Q4 2025 to a low of $40.3 million in Q2 2022.
- A 5-year average of $66.2 million and a median of $67.0 million in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2022 — Receivables - Net decreased 5.43% — and 2023, when it jumped 90.29%.
- Tracing HRTX's Receivables - Net over 5 years: stood at $52.0 million in 2022, then rose by 15.54% to $60.1 million in 2023, then soared by 31.17% to $78.9 million in 2024, then grew by 13.57% to $89.6 million in 2025, then declined by 6.58% to $83.7 million in 2026.
- The last three Receivables - Net figures came in at $83.7 million (Q1 2026), $89.6 million (Q4 2025), and $81.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.57 Mn |
| Jun 30, 2026 | 89.57 Mn |
| Mar 31, 2026 | 83.69 Mn |
| Mar 31, 2026 | 83.69 Mn |
| Dec 31, 2025 | 89.59 Mn |
| Dec 31, 2025 | 89.59 Mn |
| Sep 30, 2025 | 81.05 Mn |
| Sep 30, 2025 | 81.05 Mn |
| Jun 30, 2025 | 79.93 Mn |
| Jun 30, 2025 | 79.93 Mn |
| Mar 31, 2025 | 78.74 Mn |
| Mar 31, 2025 | 78.74 Mn |
| Dec 31, 2024 | 78.88 Mn |
| Dec 31, 2024 | 78.88 Mn |
| Sep 30, 2024 | 67.04 Mn |
| Sep 30, 2024 | 67.04 Mn |
| Jun 30, 2024 | 73.71 Mn |
| Jun 30, 2024 | 73.71 Mn |
| Mar 31, 2024 | 65.32 Mn |
| Mar 31, 2024 | 65.32 Mn |